Cargando…

P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL

Detalles Bibliográficos
Autores principales:	Liang, Emily, Hirayama, Alexandre, Kimble, Erik, Portuguese, Andrew, Albittar, Aya, Chapuis, Aude, Shadman, Mazyar, Till, Brian, Cassaday, Ryan, Milano, Filippo, Kiem, Hans-Peter, Turtle, Camesron, Maloney, David, Gauthier, Jordan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429589/ http://dx.doi.org/10.1097/01.HS9.0000969368.47239.5b

Ejemplares similares

Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
por: Liang, Emily C., et al.
Publicado: (2023)

2711. Viral encephalitis after chimeric antigen receptor (CAR)-modified T-cell therapy: A Retrospective Cohort Study
por: Kampouri, Eleftheria, et al.
Publicado: (2023)

P1097: CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY
por: Shadman, Mazyar, et al.
Publicado: (2023)

Vaccinations in CLL: implications for COVID-19
por: Shadman, Mazyar, et al.
Publicado: (2021)

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study
por: Iovino, Lorenzo, et al.
Publicado: (2022)

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
por: Gauthier, Jordan, et al.
Publicado: (2022)

Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy
por: Juluri, Krishna R., et al.
Publicado: (2022)

Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL
por: Collins, McKensie A., et al.
Publicado: (2022)

SAT616 Differentiating Resistant Prolactinoma From Macroprolactinemia
por: Lacount, Steven, et al.
Publicado: (2023)

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy
por: Sheih, Alyssa, et al.
Publicado: (2020)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
por: Wang, Jinghua, et al.
Publicado: (2018)

P621: REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT
por: Shadman, Mazyar, et al.
Publicado: (2023)

616. Predicting Misdiagnoses of Infectious Disease in Emergency Department Visits
por: Chapman, Alec B, et al.
Publicado: (2021)

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
por: Zhang, Hui, et al.
Publicado: (2020)

The Impact of B-Cell-Directed Therapy on Sars-Cov-2 Vaccine Efficacy in CLL: 1-Year Follow up
por: Ujjani, Chaitra S., et al.
Publicado: (2022)

Andante in F major, K. 616, for flute, oboe, clarinet, and bassoon /
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1975)

Complications of percutaneous vertebroplasty: An analysis of 1100 procedures performed in 616 patients
por: Saracen, Agnieszka, et al.
Publicado: (2016)

MON-616 Potential Relationship between Hypothyroidism and Periodontal Disease Severity
por: Yerke, Lisa, et al.
Publicado: (2019)

616 Application of Antibacterial Thermosensitive Collagen-Based Hydrogel in Wound Healing
por: Amiri, Nafise, et al.
Publicado: (2022)

THU616 Analysis Of Germline Mutations In Patients With Sporadic Adrenocortical Carcinoma
por: Terzolo, Massimo, et al.
Publicado: (2023)

A multivariate CAR model for mismatched lattices()
por: Porter, Aaron T., et al.
Publicado: (2014)

$\pi^{-}$ proton scattering at 516, 616, 710, 887,and 1085 MeV
por: Grard, F, et al.
Publicado: (1961)

616. Candidemia in a Dominican tertiary care hospital: Six years of history
por: Rojas-Fermin, Rita A, et al.
Publicado: (2023)

Improving Outcomes for Patients With Chronic Lymphocytic Leukemia
por: Shadman, Mazyar, et al.
Publicado: (2020)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023)

Bicistronic CAR-T cells targeting CD123 and CLL1 for AML to reduce the risk of antigen escape
por: Xie, Danni, et al.
Publicado: (2023)

196. Antibodies to Vaccine-preventable Infections After CAR-T Cell Immunotherapy for B Cell Malignancies
por: Walti, Carla S, et al.
Publicado: (2020)

Objectively Measured Daily Step Counts and Prevalence of Frailty in 3,616 Older Adults
por: Watanabe, Daiki, et al.
Publicado: (2020)

Prognostic Nutritional Index as a Predictor of Mortality in 101,616 Patients Undergoing Hemodialysis
por: Miyasato, Yoshikazu, et al.
Publicado: (2023)

Hematopoietic Cell Transplantation for Older Patients with MDS
por: Shadman, Mazyar, et al.
Publicado: (2014)

P647: RACIAL DISPARITIES IN REAL-WORLD TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CLL
por: Rhodes, Joanna, et al.
Publicado: (2023)

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
por: Mato, Anthony R., et al.
Publicado: (2018)

SUN-616 A Rapidly Enlarging Neck Mass in a 59-Year-Old Woman
por: Nath, Priti, et al.
Publicado: (2019)

Disparities in Cost and Access by Caseload for Arthroscopic Rotator Cuff Repair: An Analysis of 18,616 Cases
por: Li, Lambert, et al.
Publicado: (2019)

RP11-616M22.7 recapitulates imatinib resistance in gastrointestinal stromal tumor
por: Shao, Yebo, et al.
Publicado: (2021)

Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses
por: Muchamuel, Tony, et al.
Publicado: (2023)

Childhood trauma fatality and resource allocation in injury control programs in a developing country
por: Roudsari, Bahman S, et al.
Publicado: (2006)

Cytokines in CAR T Cell–Associated Neurotoxicity
por: Gust, Juliane, et al.
Publicado: (2020)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1rno8o16j4sfba1u22024sro99